

ABEC supports Serum Institute for large scale COVID-19 vaccine manufacturing

01 October 2020 | News

ABEC's Custom Single Run (CSR®) technology to support production of ~1 billion doses of Novavax COVID-19 vaccine



ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing based in the US, has announced it is supporting [Serum Institute](#) of India Pvt. Ltd. (SIIPL) in Pune by delivering six 4,000L CSR bioreactors for the manufacturing of [Novavax' COVID-19 vaccine](#) candidate, NVX-CoV2373.

Serum Institute, the world's largest vaccine manufacturer by number of doses, will utilize ABEC's single-use technologies to advance a global supply of NVX-CoV2373 throughout India and low- and middle-income countries.

Serum Institute's new facility will be the largest single-use bioreactor-based vaccine manufacturing line in the world. ABEC's 4,000L CSR single-use bioreactors are the largest in the industry by a factor of two, allowing Serum Institute to double productivity per unit floorspace and achieve the lowest possible cost per dose.

Leveraging its global presence, ABEC is manufacturing the single-use bioreactors and disposable containers (DC) in its US and Ireland facilities to meet Serum Institute's accelerated schedule. ABEC's multi-site global ISO-7 cleanrooms ensure a robust supply chain with the industry's shortest DC lead times, enabling Serum Institute to begin production in early 2021.